Hikma Pharmaceuticals PLC (FRA:H5P)
€ 22 0.4 (1.85%) Market Cap: 4.89 Bil Enterprise Value: 5.78 Bil PE Ratio: 27.25 PB Ratio: 2.33 GF Score: 89/100

Full Year 2020 Hikma Pharmaceuticals PLC Earnings Call (Q&A Session) Transcript

Feb 25, 2021 / 10:00AM GMT
Release Date Price: €26.6 (-4.32%)
Layan Kalisse

Okay. Hi, everyone. It looks like we have everyone in the room. Welcome, and thank you for joining us. Just before we start, I just want to remind everyone how this session is going to work. (Operator Instructions) And with that, I will hand it over to Siggi.

Sigurdur Oli Olafsson
Hikma Pharmaceuticals PLC - CEO & Executive Director

Thanks, Layan. Good morning, everyone. Welcome to this virtual call. This has started to be normal, which wasn't normal a year ago. So I'm not going to have a long introduction. I just want to refer you to -- that you have hopefully listened to the prerecorded presentation. So we are not going to repeat that here in the beginning of the meeting. I'm sure there's a lot of questions. I think, overall, we are very, very pleased with the result of 2020. Our core revenue up 6% to $2.3 billion, and our core operating profit up 11% to $566 million. All 3 businesses are growing organically.

Injectables business, growing 10% on top line, 12% on the bottom line. Clearly, a lot of volatility around the demand in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot